• 8 July 2009
  • News
  • By

GE Healthcare makes India business stronger

GE Healthcare makes India business stronger
GE Healthcare Life Sciences provides cutting-edge technology products and processes to  pharma, biopharma and biotechnology companies and major academic and research institutions globally.

Headquartered in the UK, GE Healthcare is a $17-billion unit of General Electric, one of the world’s largest diversified conglomerates. Worldwide, GE Healthcare employs more than 46,000 and its products are used in about 100 countries. The company’s India business recorded revenue of Rs 120 crore for the year ending March 2008-09.
GE Healthcare works in the primary areas of healthcare systems (diagnostic imaging and clinical systems), medical diagnostics, surgery, healthcare IT solutions and life sciences. Over the years, the company has significantly increased its focus on its life sciences business in India, driven largely by the growth in the domestic biotechnology sector. Last year, it substantially increased its commercial footprint and service capabilities in India to cater to the customers’ needs faster and more efficiently.
 GE Healthcare Life Sciences has been a key supplier of bioprocess, protein purification, chromatography, columns, media and filtration needs to the major players in India in the biotech space and GE’s products and  services are generally regarded by customers as the best-in-class. With around 30 years of experience in biopharmaceuticals, their products and solutions are generally considered to be the gold standard in biopharmaceutical production. Anurag Gupta, managing director, GE Healthcare Life Sciences claims, “About 95 percent of around 120 FDA-approved biopharmaceuticals are manufactured using GE Healthcare Life Sciences’ products. This level of proven leadership is important everywhere and is valued by companies in India.”
GE Healthcare Life Sciences has a service team and commercial team  in India with offices at Bangalore, Delhi, Chennai, Mumbai, Hyderabad, Kolkata, Lucknow, Pune and Chandigarh.
GE Healthcare Life Sciences has introduced a new portfolio of ready-to-use systems and devices designed for biopharmaceutical production. The ReadyToProcess  portfolio is a range of products designed to meet the biopharmaceutical industry’s need for increased speed, simplicity and safety for all areas of bioprocessing—from cell culture and fermentation to final purification.
GE Healthcare Life Sciences recently  acquired MicroCal, a provider of innovative instruments for the study of molecular interactions in pharmaceutical, biomedical and life science research. MicroCal’s proprietary technology, which is complementary to GE Healthcare’s Biacore platform, provides scientists with detailed information across several stages of the drug discovery process, reducing the potential for late-stage drug candidate failures. 

Leave a Reply Sign in

Notify me of follow-up comments via e-mail address

Post Comment

Survey Box

National Health Policy

Is National Health Policy 2017 helpful for patients?

Send this article by email